Xeris Biopharma Holdings, Inc. (XERS)
NasdaqGS · USD · Healthcare · Drug Manufacturers - Specialty & Generic
$10.36 (+1.47%) as of
Key statistics
- Market cap
- 1.89B
- Forward P/E
- 52.68
- EPS (TTM)
- -0.10
- Dividend yield
- 0.00%
- 52-week range
- 5.25 – 11.42
- Beta
- 0.84
- Revenue (TTM)
- 335.41M
- Profit margin
- -5.12%
- Analyst target
- $12.86
- Volume
- 524.73k
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Chicago, IL, United States
- Employees
- 435
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.